GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Cyclically Adjusted Revenue per Share

Biomerica (Biomerica) Cyclically Adjusted Revenue per Share : $0.82 (As of Feb. 2024)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biomerica's adjusted revenue per share for the three months ended in Feb. 2024 was $0.060. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.82 for the trailing ten years ended in Feb. 2024.

During the past 12 months, Biomerica's average Cyclically Adjusted Revenue Growth Rate was -3.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biomerica was 12.10% per year. The lowest was -10.40% per year. And the median was -5.20% per year.

As of today (2024-05-26), Biomerica's current stock price is $0.626. Biomerica's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2024 was $0.82. Biomerica's Cyclically Adjusted PS Ratio of today is 0.76.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomerica was 14.42. The lowest was 0.68. And the median was 3.23.


Biomerica Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biomerica's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Cyclically Adjusted Revenue per Share Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.76 0.77 0.88 0.84

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.84 0.84 0.83 0.82

Competitive Comparison of Biomerica's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Biomerica's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomerica's Cyclically Adjusted PS Ratio falls into.



Biomerica Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomerica's adjusted Revenue per Share data for the three months ended in Feb. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=0.06/130.9299*130.9299
=0.060

Current CPI (Feb. 2024) = 130.9299.

Biomerica Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201405 0.222 100.373 0.290
201408 0.137 100.352 0.179
201411 0.150 99.635 0.197
201502 0.172 99.032 0.227
201505 0.198 100.333 0.258
201508 0.170 100.548 0.221
201511 0.154 100.135 0.201
201602 0.179 100.040 0.234
201605 0.172 101.355 0.222
201608 0.173 101.617 0.223
201611 0.175 101.829 0.225
201702 0.178 102.779 0.227
201705 0.170 103.256 0.216
201708 0.170 103.587 0.215
201711 0.189 104.072 0.238
201802 0.161 105.052 0.201
201805 0.130 106.148 0.160
201808 0.143 106.383 0.176
201811 0.166 106.338 0.204
201902 0.135 106.649 0.166
201905 0.122 108.048 0.148
201908 0.123 108.245 0.149
201911 0.163 108.519 0.197
202002 0.120 109.139 0.144
202005 0.247 108.175 0.299
202008 0.097 109.662 0.116
202011 0.117 109.793 0.140
202102 0.305 110.968 0.360
202105 0.086 113.576 0.099
202108 0.102 115.421 0.116
202111 0.369 117.269 0.412
202202 0.598 119.703 0.654
202205 0.412 123.323 0.437
202208 0.125 124.958 0.131
202211 0.110 125.607 0.115
202302 0.082 126.928 0.085
202305 0.067 128.314 0.068
202308 0.102 129.538 0.103
202311 0.093 129.548 0.094
202402 0.060 130.930 0.060

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biomerica  (NAS:BMRA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomerica's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.626/0.82
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomerica was 14.42. The lowest was 0.68. And the median was 3.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biomerica Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biomerica's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Industry
Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663